文献速递系统性红斑狼疮血管炎

系统性红斑狼疮患者10年前瞻性研究中的动脉粥样硬化斑块进展与新发心血管事件:持续心血管危险因素达标与持续DORIS缓解的影响

Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission.
PubMed 文献 · Arthritis Rheumatol · 2025-01-24

该10年前瞻性研究纳入413例系统性红斑狼疮(SLE)患者与325名年龄性别匹配健康对照,评估颈动脉斑块进展及新发心血管事件。SLE患者斑块进展风险为健康对照的2.26倍,每持续达标一项心血管危险因素风险降低32%,随访中≥75%时间达DORIS缓解与进展风险降低43%相关。SLE患者10年新发心血管事件多于健康对照(8例 vs 1例),持续三抗磷脂抗体阳性与事件相关。

要点

  • SLE患者颈动脉斑块进展风险为健康对照的2.26倍(IRR 2.26,P=0.002)。
  • 每持续达标一项心血管危险因素,SLE患者斑块进展风险降低32%(IRR 0.68,P=0.004)。
  • 随访中≥75%时间达DORIS缓解与斑块进展风险降低43%相关(IRR 0.57,P=0.033)。

核心结论

  • SLE患者10年动脉粥样硬化进展风险为健康对照的2.3倍,持续心血管危险因素控制与长时间临床缓解可减轻该风险。
  • 持续三抗磷脂抗体阳性与新发心血管事件发生率增加相关。

研究设计与样本

  • 前瞻性研究,分析738次颈动脉超声测量(SLE患者413次,年龄性别匹配健康对照325次),评估基线至3年、7年、10年随访的新发斑块。
  • 采用多变量混合效应泊松回归模型分析斑块进展的潜在预测因素,并用单变量Cox回归分析10年新发心血管事件的潜在关联。

主要发现

  • SLE患者颈动脉斑块进展风险为健康对照的2.26倍(IRR 2.26,P=0.002)。
  • SLE患者随访期间每持续达标一项心血管危险因素(包括血压、血脂、吸烟、体重和体力活动),斑块进展风险降低32%(IRR 0.68,P=0.004)。
  • 随访中≥75%时间达DORIS缓解与动脉粥样硬化进展风险降低43%相关(IRR 0.57,P=0.033)。
  • SLE患者10年新发心血管事件风险高于健康对照(8例 vs 1例,置换检验log-rank P=0.036),且与持续三抗磷脂抗体阳性相关。

关键数值与推荐

  • SLE患者较健康对照颈动脉斑块进展风险升高(IRR 2.26,P=0.002)。
  • 每持续达标一项心血管危险因素,SLE患者斑块进展风险降低(IRR 0.68,P=0.004)。
  • 随访中≥75%时间达DORIS缓解者动脉粥样硬化进展风险降低(IRR 0.57,P=0.033)。
  • SLE患者10年新发心血管事件8例,健康对照1例(置换检验log-rank P=0.036)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiovascular disease (CVD) is a leading cause of death in individuals with systemic lupus erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in patients with SLE over a 10-year follow-up. METHODS: We prospectively analyzed 738 carotid ultrasound measurements (413 in patients with SLE and 325 in age/sex-matched healthy controls [HCs]) to assess new plaque development from baseline to 3-, 7-, and 10-year follow-up. Multivariate mixed-effects Poisson regression models examined potential predictors of plaque progression, including patient characteristics, Systemic Coronary Risk Evaluation, traditional cardiovascular risk factor (CVRF) target attainment, Definition of Remission in SLE (DORIS), medications, and persistent triple anti-phospholipid antibody (aPL) positivity during follow-up. Ten-year incident cardiovascular events were recorded, and univariate Cox regression analysis assessed potential associations. RESULTS: Patients with SLE had a 2.3-fold higher risk of carotid plaque progression than HCs (incidence rate ratio [IRR] 2.26, P = 0.002). Plaque progression risk in patients with SLE was reduced by 32% (IRR 0.68, P = 0.004) per each sustainedly attained CVRF target during follow-up, including blood pressure, lipids, smoking, body weight, and physical activity. DORIS achievement ≥75% of follow-up was associated with a 43% decrease in atherosclerosis progression risk (IRR 0.57, P = 0.033). Ten-year risk of incident cardiovascular events was higher in individuals with SLE than HCs (eight versus one event, permutation-based log-rank P = 0.036) and was associated with persistent triple aPL positivity. CONCLUSION: Patients with SLE experience a 2.3-fold higher 10-year atherosclerosis progression risk than HCs, mitigated by sustained CVRF control and prolonged clinical remission. Persistent triple aPL positivity is associated with increased incidence of CVD events.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Papazoglou N, Sfikakis PP, Tektonidou MG, et al. Atherosclerotic Plaque Progression and Incident Cardiovascular Events in a 10-Year Prospective Study of Patients With Systemic Lupus Erythematosus: The Impact of Persistent Cardiovascular Risk Factor Target Attainment and Sustained DORIS Remission. Arthritis Rheumatol. 2025. PMID: 39721769. doi:10.1002/art.43097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。